Gene and Cell Therapy – News and Features

The studies evaluated injections of HypoThermosol, CryoStor, or control phosphate buffered saline into healthy rodents.

The collaboration with Kyoto researcher will allow Novocell to explore the creation of human islet cells from induced pluripotent stem cells.

A study at the Salk Institute confirmed that dysfunctional human astrocytes turn against their charges and kill off healthy motor neurons.

The acquisition expands Alnylam intellectual property estate, includes several early and broad RNAi patent families.

The collaboration aims to advance development of Neuralstem's human spinal cord neural stem cell therapies.

Horizon gains world-wide exclusive rights to a key genetic process behind its GENESIS platform used to create X-MAN cell-lines.

The collaboration will evaluate menstrual stem cells for future potential breast cancer therapy.

Geron Corporation announced the publication of preclinical data on TAT2, a small molecule telomerase activator.

Incyte Corporation announced the presentation of clinical results from a 28-day Phase IIa trial of INCB18424, its orally available janus kinase (JAK) inhibitor, in patients with rheumatoid arthritis (RA). Results from the 50-patient placebo-controlled trial demonstrated that three of the four doses of INCB18424 evaluated (15 mg BID, 25 mg BID and 50 mg QD) produced impressive clinical benefits and all of the doses were well tolerated. American College of Rheumatology (ACR) 20, ACR50, ACR70 a

Multiple US medical centers activly enrolling patients into first Phase 2 trial of allogeneic stem cells for congestive heart failure.